Aptorum Group
Market Cap
US$467.5m
Last Updated
2019/10/16 00:41 UTC
Data Sources
Company Financials +
Executive Summary
Aptorum Group Limited, a pharmaceutical company, develops and commercializes a range of therapeutic and diagnostic technologies to treat unmet medical needs.
Snowflake
Fundamentals
Adequate balance sheet with limited growth.
Share Price & News
How has Aptorum Group's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
0.4%
APM
4.6%
US Biotechs
3.4%
US Market
1 Year Return
n/a
APM
-10.1%
US Biotechs
5.4%
US Market
Return vs Industry: Insufficient data to determine how APM performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how APM performed against the US Market.
Shareholder returns
| APM | Industry | Market | |
|---|---|---|---|
| 7 Day | 0.4% | 4.6% | 3.4% |
| 30 Day | -5.1% | -2.4% | -1.0% |
| 90 Day | -28.1% | -2.1% | -0.4% |
| 1 Year | n/a | -9.4%-10.1% | 7.7%5.4% |
| 3 Year | n/a | 14.9%10.9% | 46.2%36.8% |
| 5 Year | n/a | 2.3%-2.7% | 65.6%47.5% |
Price Volatility Vs. Market
How volatile is Aptorum Group's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 days ago | Simply Wall St
Is Aptorum Group (NASDAQ:APM) In A Good Position To Invest In Growth?1 month ago | Simply Wall St
Do Insiders Own Shares In Aptorum Group Limited (NASDAQ:APM)?5 months ago | Simply Wall St
Could The Aptorum Group Limited (NASDAQ:APM) Ownership Structure Tell Us Something Useful?Valuation
Is Aptorum Group undervalued compared to its fair value and its price relative to the market?
18.74x
Price to Book (PB) ratio
Share Price vs. Fair Value
Undervalued: Insufficient data to calculate APM's fair value to establish if it is undervalued.
Significantly Undervalued: Insufficient data to calculate APM's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: APM is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: APM is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
Low PEG Ratio: Insufficient data to calculate APM's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: APM is overvalued based on its PB Ratio (18.7x) compared to the US Biotechs industry average (2.6x).
Next Steps
Future Growth
How is Aptorum Group forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
-11.6%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: APM is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: APM is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: APM is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: APM's revenue (50.1% per year) is forecast to grow faster than the US market (7.3% per year).
High Growth Revenue: APM's revenue (50.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
High Future ROE: APM is forecast to be unprofitable in 3 years.
Next Steps
Past Performance
How has Aptorum Group performed over the past 5 years?
-163.0%
Last years earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: APM is unprofitable, and there is insufficient past data to establish if their past 5-year earnings growth rate was positive.
Accelerating Growth: Unable to compare APM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: APM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (78.4%).
Return on Equity
High ROE: APM has a negative Return on Equity (-80.09%), as it is currently unprofitable.
Return on Assets
ROA vs Industry: APM is currently unprofitable, so its Return on Assets is negative.
Return on Capital Employed
ROCE Improving: APM is currently unprofitable, so its Return on Capital Employed is negative.
Next Steps
Financial Health
How is Aptorum Group's financial position?
Financial Position Analysis
Short Term Liabilities: APM's short term assets ($7.7M) exceeds its short term liabilities ($597.1K)
Long Term Liabilities: APM's short term assets (7.7M) exceeds its long term liabilities (120.9K)
Debt to Equity History and Analysis
Debt Level: APM is debt free.
Reducing Debt: APM had no debt 5 years ago.
Balance Sheet
Inventory Level: APM has a high level of physical assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if APM's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: APM has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: APM has less than a year of cash runway if free cash flow continues to reduce at historical rates of -41.2% each year
Next Steps
Dividend
What is Aptorum Group's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: Unable to evaluate APM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate APM's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stable Dividend: Insufficient data to determine if APM's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if APM's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of APM's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
What is the CEO of Aptorum Group's salary, the management and board of directors tenure and is there insider trading?
1.9yrs
Average management tenure
CEO
Ian Huen (39yo)
2yrs
Tenure
Mr. Chung Yuen Huen also known as Ian, is the Founder of Aptorum Group Limited and has been its Chief Executive Officer since October 1, 2017 and serves as its Executive Director. Mr. Huen has been Chairma ...
Management Age and Tenure
1.9yrs
Average Tenure
38.5yo
Average Age
Experienced Management: APM's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Board Age and Tenure
2.0yrs
Average Tenure
49yo
Average Age
Experienced Board: APM's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Management Team
Thomas Lee (46yo)
Head of Research & Development
- Tenure: 0.5yrs
Clark Cheng (39yo)
Chief Medical Officer & Executive Director
- Tenure: 0yrs
Darren Lui (38yo)
President & Executive Director
- Tenure: 0yrs
Ian Huen (39yo)
Founder
- Tenure: 2yrs
Sabrina Khan (38yo)
Chief Financial Officer
- Tenure: 2yrs
Angel Ng (38yo)
Chief Operating Officer
- Tenure: 0.5yrs
Board Members
Mirko Scherer (50yo)
Independent Non-Executive Director
- Tenure: 2yrs
Charles Bathurst (64yo)
Independent Non-Executive Director
- Tenure: 2yrs
Keith Chan (72yo)
Member of Scientific Advisory Board
- Tenure: 0.5yrs
Douglas Arner (49yo)
Independent Non-Executive Director
- Tenure: 1.5yrs
Justin Wu (49yo)
Independent Non-Executive Director
- Tenure: 2yrs
Clark Cheng (39yo)
Chief Medical Officer & Executive Director
- Tenure: 0yrs
Darren Lui (38yo)
President & Executive Director
- Tenure: 0yrs
Ian Huen (39yo)
Founder
- Tenure: 2yrs
Company Information
Aptorum Group Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Aptorum Group Limited
- Ticker: APM
- Exchange: NasdaqGM
- Founded: 2010
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$467.465m
- Shares outstanding: 29.04m
- Website: https://www.aptorumgroup.com
Number of Employees
Location
- Aptorum Group Limited
- Guangdong Investment Tower
- 17th Floor
- Central
- Hong Kong
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| APM | NasdaqGM (Nasdaq Global Market) | Yes | Class A Ordinary Shares | US | USD | Dec 2018 |
Biography
Aptorum Group Limited, a pharmaceutical company, develops and commercializes a range of therapeutic and diagnostic technologies to treat unmet medical needs. It focuses on developing various drug molecules ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/10/16 00:41 |
| End of Day Share Price | 2019/10/15 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.